Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Ohlsson, Arne ^a   Aher, Sanjay M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Neonatology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PLACEBO;

BONE PAIN; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HUMAN; HYPERTENSION; INCIDENCE; LOW BIRTH WEIGHT; MORBIDITY; MORTALITY; NECROTIZING ENTEROCOLITIS; NERVE CELL DIFFERENTIATION; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PREMATURE LABOR; PRIORITY JOURNAL; RASH; REVIEW; RISK REDUCTION; SEIZURE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; ANEMIA, NEONATAL; BLOOD; CAUSE OF DEATH; DRUG ADMINISTRATION; META ANALYSIS; NEWBORN; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; UTILIZATION;

AGE FACTORS; ANEMIA, NEONATAL; CAUSE OF DEATH; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84942748885     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004863.pub4     Document Type: Review

References (112)

1. Al-Kharfy T, Smyth JA, Wadsworth L, Krystal G, Fitzgerald C, Davis J, et al. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. Journal of Pediatrics 1996;129(1):89-96.
2. Arif B, Ferhan K. Recombinant human erythropoietin therapy in low-birthweight preterm infants: a prospective controlled study. Pediatrics International 2005;47(1):67-71.
3. Avent M, Cory BJ, Galpin J, Ballot DE, Cooper PA, Sherman G, et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics 2002;48(4):227-33.
4. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics 1992;121(1):98-102.
5. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archieves of Disease in Childhood Fetal Neonatal Edition 1998;79(1):F44-8.
6. Chang L, Liu W, Liao C, Zhao X. Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University 1998;18(4):239-42.
7. Fauchère J-C, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122(2):375-82.
8. Haiden N, Cardona F, Schwindt J, Berger A, Kuhle S, Homoncik M, et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis 2005;93(1):118-23.
9. He JS, Huang ZL, Yang H, Weng KZ, Zhu SB. Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi 2008;10(5):586-8.
10. Khatami SF, Mamouri G, Torkaman M. Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics 2008;75(12):1227-30.
11. Lauterbach R, Kachlik P, Pawlik D, Bajorek I. Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska 1995;70(9):739-44.
12. Lima-Roogel V, Torres-Montes A, Espinosa Griesse S, Villegas Alvarez C, Hernandez-Sierra F, Bissett Mandeville P, et al. Efficacy of early erythropoietin use in critically ill very-low-birth-weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre 1998;43(3):191-5.
13. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine 1994;330(17):1173-8.
14. Maier RF, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics 2002;141(1):8-15.
15. Meister B, Maurer H, Simma B, Kern H, Ulmer H, Hittmair A, et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells 1997;15(5):359-63.
16. Meyer MP, Sharma E, Carsons M. Recombinant erythropoietin and blood transfusion in selected infants. Archieves of Disease in Childhood. Fetal Neonatal Edition 2003;88(1):F41-5.
17. Obladen M, Maier R, Segerer H, Grauel EL, Holland BM, Stewart G, et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European Randomized Multicenter Trial. Contributions to Nephrology 1991;88:314-26.
18. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. Journal of Pediatrics 1995;126(3):421-6.
19. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo-controlled study. Journal of Pediatrics 1997;131(5):661-5.
20. Ehrenkranz RA, Ohls RK, Das A, Vohr BR. Neurodevelopmental outcome and growth at 18-22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research 2002;51:291A.
21. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004;114(5):1287-91.
22. Ohls RK, Ehrenkranz RA, Lemons JA, Korones SB, Stoll BJ, Stark AR, et al. A multicenter randomized double-masked placebo-controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research 1999;45:216 A.
23. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108(4):934-42.
24. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108(4):934-42.
25. Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M, et al. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 2013;132(1):e119-27.
26. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Schrader R, et al. Neurocognitive outcomes at 18-22 months corrected age are improved in preterm infants administered darbepoetin or eryhtopoietin. Abstracts2view. 2013:E-PAS2013:1165.5.
27. Ohls RK, McConaghy S, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18-22 months. Abstract2view; E-PAS2013:2924.485. 2013.
28. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?. European Journal of Pediatrics 2000;159(8):627-8.
29. Salvado A, Ramolfo P, Escobar M, Nunez A, Aguayo I, Standen J, et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile 2000;128(12):1313-7.
30. Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995;95(1):1-8.
31. Soubasi V, Kremenopoulos G, Diamandi E, Tsantali C, Tsakiris D. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research 1993;34(5):675-9.
32. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics 1995;127(2):291-7.
33. Soubasi V, Kremenopoulos G, Tsantali C, Savopoulou P, Mussafiris C, Dimitrou M. Use of erythropoietin and its effects on blood lactate and 2, 3-diphosphoglycerate in premature neonates. Biology of the Neonate 2000;78(4):281-7.
34. Yasmeen BHN, Chowdhury MA, Hoque MM, Hossain MM, Jahan R, Aktar S. Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin 2012;38(3):119-23.
35. Yeo CL, Choo S, Ho LY. Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health 2001;37(4):352-8.
36. Amin AA, Alzahrani DM. Efficacy of erythropoietin in premature infants. Saudi Medical Journal 2002;23(3):287-90.
37. Bierer R, Peceney MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006;118(3):e635-40.
38. Brown MS, Keith JF 3rd. Comparison between two and five doses a week of recombinant erythropoietin for anemia of prematurity: a randomized trial. Pediatrics 1999;104(2 Pt 1):210-5.
39. Costa S, Romagnoli C, Zuppa AA, Cota F, Socorrano A, Gallini F, et al. How to administrate erythropoietin, intravenous or subcutaneous?. Acta Paediatrica 2013;102(6):579-83.
40. Fearing MK, Eades B, Martinez B, Wood N, Accardo L, Browning CA, et al. Cost effective use of recombinant erythropoietin (HuEPO) in very low birth weight (VLBW) infants for improved clinical outcomes. Pediatric Research 2002;51:310A.
41. 12 on the transfusion requirements of extremely low birth weight infants. Pediatrics 2006;118(5):2004-13.
42. Haiden N, Klebermass K, Cardona F, Schwindt J, Berger A, Kohlhauser-Vollmuth C, et al. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics 2006;118(1):180-8.
43. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122(2):383-91.
44. Klipp M, Holzwarth AU, Poeschl JM, Nelle M, Linderkamp O. Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants. Acta Paediatrica 2007;96(2):253-6.
45. Krallis N, Cholevas V, Mavridis A, Georgiou I, Bourantas K, Andronikou S. Effect of recombinant human erythropoietin in preterm infants. European Journal of Haematology 1999;63(2):71-6.
46. Maggio L, Scorrano A, Cota F, Gallini F, Romagnoli C, Zuppa AA. Randomized controlled trial on the effectiveness of early recombinant erythropoietin administered to preterm infants by continuous intravenous versus subcutaneous route. Pediatric Academic Societies' Annual Meeting. 2007:E-PAS2007:616315.9.
47. Maier RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. Journal of Pediatrics 1998;132(5):866-70.
48. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. Journal of Pediatrics 1996;128(4):518-23.
49. Saeidi R, Banihashem A, Hammoud M, Gholami M. Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity. Iranian Red Crescent Medical Journal 2012;14(3):178-81.
50. Soubasi V, Pouliou T, Tsantali C, Lithoxopoulou M, Drossou V, Kremenopoulos G. Is erythropoietin (EPO) a multifunctional tissue protective cytokine? Follow-up of rHuEPO treated prematures. Pediatric Academic Societies' Annual Meeting. 2005:PAS 2005:57:164.
51. Soubasi V, Petridou S, Sarafidis K, Agathi T, Griva M, Drossou V. High dose of erythropoietin in premature neonates: Short-term outcomes. Pediatric Academic Societies' Annual Meeting. 2009:E-PAS2009:5506.105.
52. Turker G, Sarper N, Gokalp S, Usluer H. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants. American Journal of Perinatology 2005;22(8):449-55.
53. Vázquez López MÁ, Llamas MÁ, Galera R, Sanchez AR, Lendinez F, Gonzalez-Ripoll M, et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. Journal of Perinatology 2011;31(2):118-24.
54. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124(2):e218-26.
55. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004868.pub2]
56. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004865.pub2]
57. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD004868.pub3]
58. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD004865.pub2]
59. Aulak PK, Malik P, Siassi B, Sardesai SR, Ramanathan R. Erythropoietin treatment and >/= stage III retinopathy of prematurity in very low birth weight (VLBW) infants. American Pediatric Societies' Annual Meeting. 2002:Abstract 2135.
60. Baer VL, Lambert DK, Henry E, Snow GL, Christensen RD. Red blood cell transfusion of preterm neonates with grade 1 intraventricular hemorrhage is associated with extension to a grade 3 or 4 hemorrhage. Transfusion 2011;51(9):1933-9.
61. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, et al. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009;123(1):313-8.
62. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9.
63. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. Journal of Pediatrics 2011;158(3):403-9.
64. Brown MS, Phibbs RH, Garcia JF, Dallman PR. Postnatal changes in erythropoietin levels in untransfused premature infants. Journal of Pediatrics 1983;103(4):612-7.
65. Brown MS, Berman ER, Luckey D. Prediction of the need for transfusion during anemia of prematurity. Journal of Pediatrics 1990;116(5):773-8.
66. Brown MS, Barón AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. Journal of the American Association for Pediatric Ophthalmology and Strabismus 2006;10(2):143-9.
67. Cohen A, Manno C. Transfusion practices in infants receiving assisted ventilation. Clinics in Perinatology 1998;25(1):97-111.
68. Dallman PR. Anemia of prematurity. Annual Review of Medicine 1981;32:143-60.
69. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biology of the Neonate 2001;79(3-4):228-35.
70. De Luca T, StolfiI, Chiello D, Santillo C, Colarizi P. Recombinant human erythropoietin (rhEPO): A possible risk factor for retinopathy of prematurity (ROP). Pediatric Academic Societies' Annual Meeting. 2001:Abstract 2238.
71. Dolfin T, Skidmore MB, Fong KW, Hoskins EM, Shennan AT. Incidence, severity, and timing of subependymal and intraventricular hemorrhages in preterm infants born in a perinatal unit as detected by serial real-time ultrasound. Pediatrics 1983;71(4):541-6.
72. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001;84:Supplement 1:3-10.
73. Finch CA. Erythropoiesis, erythropoietin and iron. Blood 1982;60:1241-6.
74. Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis. Journal of Perinatology 2002;22(2):108-11.
75. Hesse L, Eberl W, Schlaud M, Poets CF. Blood transfusion. Iron load and retinopathy of prematurity. European Journal of Pediatrics 1997;156(6):465-70.
76. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
77. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
78. Juul SE. Erythropoietin in the neonate. Current Problems in Pediatrics 1999;29(5):133-49.
79. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatrica Supplement 2002;91(438):36-42.
80. Kirpalani H, Zupancic JA. Do transfusions cause necrotizing enterocolitis? The complementary role of randomized trials and observational studies. Seminars in Perinatology 2012;36(4):269-76.
81. Klaus MH, FanaroffAA. Care of the High-risk Neonate (Third edition). Philadelphia, London, Toronto: W.B. Saunders Campany, 1986.
82. Klaus M, FanaroffA. Asistencia del recien nacido de alto riesgo, 3e edicion. Panamericana, 1987.
83. Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis. Journal of Perinatology 2004;24(1):24-9.
84. Lee DA, Slagle TA, Jackson TM, Evans CS. Reducing blood donor exposures in low birth weight infants by the use of older, unwashed packed red blood cells. Journal of Pediatrics 1995;126(2):280-6.
85. Liu A, Fayard E, Dunbar J, Chan A, Niemeyer M. High-dose recombinant human erythropoietin may increase the incidence and severity of ROP in premature infants. Pediatric Academic Societies' 2006 Annual Meeting. http://www.abstracts2view.com/pas/. 2006:E-PAS2006:59:4134.6.
86. Maier RF, Sonntag J, Walka MM, Liu G, Metze BC, Obladen M. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. Journal of Pediatrics 2000;136(2):220-4.
87. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. Erythropoietin as a retinal angiogenic factor. New England Journal of Medicine 2005;353(20):2190-1.
88. Manzoni P, Memo L, Maestri A, Saia OS, Farina D. Use of erythropoietin is associated with threshold retinopathy of prematurity (ROP) in preterm extremely-low-birth-weight neonates: A retrospective, cohort study from two large tertiary NICUs in Italy. Pedaitric Academic Societies' Annual Meeting. 2008:E-PAS2008:635836.2.
89. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, et al. HLF/HIF-2 alpha is a key factor in retinopathy of prematurity in association with erythropoietin. The EMBO Journal 2003;22(5):1134-46.
90. Musante G, Gederlini A, Prudent L, the Neocosur Collaborative Network. Treatment with erythropoietin and incidence of retinopathy of prematurity in ELBW infants. Pediatric Academic Societies' 2006 Annual Meeting. http://www.abstracts2view.com/pas/. 2006:E-PAS2006:59:3602.476.
91. Ohls RK. The use of erythropoietin in neonates. Clinics in Perinatology 2000;27(3):681-96.
92. Ohls RK. Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Journal of Pediatrics 2002;141(1):3-6.
93. Ohls RK. Why study erythropoietin. Acta Paediatrica 2013;102(6):567-8.
94. Rangaswamy N, Galante A, Collin M, Mhanna MJ. Effect of erythropoietin (EPO) on neurodevelopmental outcomes and retinopathy of prematurity (ROP) in extremely low birth weight infants. Pediatric Academic Societies' Annual Meeting. 2011:E-PAS20112916.216.
95. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
96. Rudzinska IM, Kornacka MK, Pawluch R. Treatment with human recombinant erythropoietin and frequency of retinopathy of prematurity [Leczenie preparatami ludzkiej rekombinowanje erytropoetyny a czestosc retionpatii u noworodkow przedwczesnie urodzonych]. Przeglad Lekarski 2002;59 Supplement 1:83-5.
97. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289(9):1124-9.
98. Shah NC, Kim R, Jadav P, Cohen LM, Baptiste DJ, Weedon J. Effect of recombinant human erythropoietin (rhEPO) on the development of retinopathy of prematurity (ROP). Pediatric Academic Societies Annual Meeting. 2005:57;546.
99. Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohen LM, Kim MR. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. American Journal of Perinatology 2010;27(1):67-71.
100. Shannon KM. Recombinant human erythropoietin in neonatal anemia. Clinics in Perinatology 1995;22(3):627-40.
101. Stockman JA 3rd, Oski FA. Physiological anaemia of infancy and the anaemia of prematurity. Clinics in Hematology 1978;7(1):3-18.
102. Stockman JA 3rd. Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatric Clinics of North America 1986;33(1):111-28.
103. Strauss RG. Current issues in neonatal transfusions. Vox Sanguinis 1986;51(1):1-9.
104. Vamvakas EC, Strauss RG. Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion 2001;41(3):406-15.
105. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, et al. Single-dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology 2005;25(11):725-30.
106. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. New England Journal of Medicine 2005;353(8):782-92.
107. Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD000512.pub2]
108. Widness JA, Seward VJ, Kromer IJ, Burmeiser LF, Bell EF, Strauss RG. Changing patterns of red blood cell transfusion in very low birth weight infants. Journal of Pediatrics 1996;129(5):680-7.
109. Yu Z, Guo X, Han S, Lu J, Sun Q, Ohlsson A. Erythropoietin for term and late preterm infants with hypoxic ischemic encephalopathy. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD008316]
110. Zipursky A. Erythropoietin therapy for premature infants: cost without benefit?. Pediatric Research 2000;48(2):136.
111. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004863.pub2]
112. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD004863.pub3]